FINWIRES · TerminalLIVE
FINWIRES

スコシアバンクが今週発表されるカナダの小売売上高データをプレビュー

-- スコシアバンクによると、カナダの2月の小売売上高と3月の速報値は金曜日に発表される。 カナダ統計局は以前、2月の名目売上高が季節調整済みで前月比約1%増加したと発表していた。同行は、この数値は修正される可能性があり、これは珍しいことではないと指摘。数量と価格、セクター別の内訳といった必要な詳細情報も提供される予定だ。 スコシアバンクは、3月は不確定要素が多く、速報値のみを発表するとしている。 同行は、第1四半期の小売売上高は2024年下半期以来最速の伸びを示していると指摘。これは、第4四半期の平均値、1月の急増、そしてスコシアバンクが発表した2月の売上高速報値の数量部分に基づくもので、3月の数値は既知の情報に基づいて計算するため変更していない。 投資家は今週、より多くの情報を得ることになるが、この指標は国内総生産(GDP)における消費者の財支出と非常に強い相関関係にある。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703